Evofem up 24% premarket on positive Amphora data in STD prevention [Seeking Alpha]
Last evofem biosciences, inc earnings: 11/6 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations: evofem.com
Seeking Alpha Healthcare | On the Move Evofem up 24% premarket on positive Amphora data in STD prevention Dec. 2, 2019 7:53 AM ET Evofem Biosciences, Inc. (EVFM) Douglas W. House Thinly traded micro cap Evofem Biosciences (NASDAQ: positive topline results AMPREVENCE The study met the primary and secondary endpoints with a favorable safety profile. Specifically, the chlamydia infection rate in the Amphora cohort was 4.9% (n=14/288) at month 4 compared to 9.8% (n=28/287) for placebo (p=0.024). The gonorrhea infection rate was 0.7% (n=2/280) versus 3.2% (n=9/277) for control (p=0.03). The company intends to submit the data for presentation at a future medical conference. An End-of-Phase 2 meeting with the FDA is next up. Management will host a conference call this morning at 8:30 am ET to discuss the results. See all stocks on the move » Now read: InMode: Not So Pretty Anymore » Try PREMIUM
[Read more]
| Impact snapshot | Event time: | EVFM | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
EVFM alerts
EVFM alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EVFM alerts
High impacting Evofem Biosciences, Inc news events
Weekly update
A roundup of the hottest topics
EVFM
News
- Evofem Biosciences Inc (NASDAQ: EVFM) had its price target raised by analysts at HC Wainwright from $9.00 to $11.00. They now have a "positive" rating on the stock.MarketBeat
- Why Evofem Biosciences Is Soaring Today [The Motley Fool]The Motley Fool
- UPDATE: Evofem Biosciences stock soars 27% premarket on news of positive results in trial of drugs for STDs [MarketWatch]MarketWatch
- Evofem Biosciences Reports Positive Top-Line Results from Phase 2b Study of Amphora® for Prevention of Chlamydia and Gonorrhea in WomenPR Newswire
- Evofem Biosciences Inc (NASDAQ: EVFM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.MarketBeat
- More
EVFM
SEC Filings
- 12/4/19 - Form 4
- 12/4/19 - Form 4
- 12/4/19 - Form 4
- EVFM's page on the SEC website
- More